The IO Quiz Show: Biomarkers for Immunotherapy

This webcast was recorded at a live event at ASCO SITC 2018. During this event, The IO Quiz Show: Biomarkers for Immunotherapy, three leading experts challenged participants with quiz questions, which formed a basis for in-depth discussions supported by slide presentations. Participants were able to test and expand their knowledge on the increasingly important role of biomarkers in immuno-oncology. The experts examined the tumor microenvironment and addressed the evidence base for, and the future potential of, current and emerging biomarkers in guiding treatment decisions and in predicting the response to immuno-oncology therapeutics. Participants also learned about the role and importance of next-generation sequencing for the evaluation of novel immune biomarkers and for daily clinical practice.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of a broad audience including medical oncologists, oncology pathologists, immunologists, and oncology nurses on the important role of biomarkers in guiding cancer immunotherapy treatment.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to do the following:

  1. Explain the clinical relevance of characterizing the tumor microenvironment in patients with cancer
  2. Describe recent advances in the field of predictive biomarkers for immunotherapy
  3. Discuss established diagnostic procedures and the potential of next-generation sequencing for assessing immune biomarkers for cancer treatment

 

FACULTY

Naiyer A. Rizvi, MD
Department of Medicine
Columbia University Medical Center
New York, NY, USA

Sacha Gnjatic, PhD
Human Immune Monitoring Center
Icahn School of Medicine at Mount Sinai
New York, NY, USA

Mario Sznol, MD
Yale Cancer Center
New Haven, CT, USA

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:

Naiyer A. Rizvi, MD

Consultant/Advisor: AstraZeneca; Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffman-La Roche Ltd., Merck & Co., Inc.; Novartis AG; Pfizer Inc.

Stock ownership: ARMO Biosciences; Gritstone Oncology, Inc.

Sacha Gnjatic, PhD

Consultant/Advisor: B4CC, Inc.; Merck & Co., Inc.; Neon Therapeutics

Grant/Research Support: Agenus Inc.; Genentech Inc.; Immune Design; Pfizer Inc.

Mario Sznol, MD

Speakers Bureau: Alexion; AstraZeneca; Bristol-Myers Squibb Company; Celldex Therapeutics; Eli Lilly and Company; Genentech, Inc.; Gritstone Oncology, Inc.; Ignyta; Innate Pharma; Incyte Corporation; MedImmune; Merck & Co., Inc; NewLink Genetics Corporation; Pierre Fabre Group; Pfizer Inc.; Shire; Seattle Genetics, Inc.; Theravance Biopharma

Consultant/Advisor: Adaptimmune Therapeutics plc; Lycera; Molecular Partners; Omniox Inc.; Symphogen

Non-faculty: Sandy Breslow; Alison Kemp; Bernard M. Abrams, MD; Cordelia Nagle; Elena Knoche; Mirella Mels; Nabil Dorkhom; Marijke Verhaaf; hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Merck & Co., Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Excerpta Medica.

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Excerpta Medica. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Excerpta Medica and Biogen do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
04/23/2018
Course expires: 
04/22/2019
Rating: 
0

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician

Accreditation Period

Course opens: 
04/23/2018
Course expires: 
04/22/2019
Please login or register to take this course.